• Home
  • Inside Kyverna
  • Our Pipeline & Expanded Access
  • Our Opportunity
  • News
  • Careers
  • Contact
Kyverna Therapeutics

News & Events

Press Releases

April 13, 2021

Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer

January 13, 2020

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

«1234

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com
kyverna_logo_inv

Links

  • Home
  • News
  • Inside Kyverna
  • Careers
  • Our Pipeline & Expanded Access
  • Contact
  • Our Opportunity

About

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

©2023 Kyverna Therapeutics, Inc. All rights reserved.
  • Privacy Policy